NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

Abstract Purpose Antiemetic guidelines recommend co-administration of targeted prophylacticmedicationsinhibitingmolecular pathwaysinvolvedinemesis.NEPAisafixedoralcombinationofa newNK1receptorantagonist(RA),netupitant(NETU300mg), and palonosetron (PALO 0.50 mg), a pharmacologically distinct 5-HT3 RA...

Full description

Bibliographic Details
Main Authors:	Aapro, Matti, Karthaus, Meinolf, Schwartzberg, Lee, Bondarenko, Igor, Sarosiek, Tomasz, Oprean, Cristina, Cardona Huerta, Servando, Hansen, Vincent, Rossi, Giorgia, Rizzi, Giada, Borroni, Maria Elisa, Rugo, Hope
Format:	Article
Language:	English
Published:	2017
Subjects:	RC Medicina Interna, Psiquiatría, Neurología
Online Access:	http://eprints.uanl.mx/18094/1/418.pdf

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of... by Aapro, Matti, Karthaus, Meinolf, Schwartzberg, Lee, Bondarenko, Igor, Sarosiek, Tomasz, Oprean, Cristina, Cardona Huerta, Servando, Hansen, Vincent, Rossi, Giorgia, Rizzi, Giada, Borroni, Maria Elisa, Rugo, Hope

Published 2017

Get full text

Article

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

Similar Items